Strong start #GU23 Neeraj Agarwal, MD, FASCO presents encouraging results: TALA + ENZA improve PFS in 1L trt for pts w/ #mCRPC OncoAlert

Great to be at #ASCOGU23 in San Francisco! Starting day 1 with Philz Coffee and learning about the latest in prostate cancer…also a reason to get back on Twitter to share what’s going on in the field! Mass General Cancer Center Rick Lee 이재방 Sophia Kamran, MD

Really helpful subgroup data from ARASENS on how patients with high vs low risk/volume disease benefit from triplet therapy. Builds on last year’s impressive initial results. Will help guide selection of therapy for pts with mHSPC. Journal of Clinical Oncology #GU23 ASCO

A big theme of PROPEL and PARPi in general is how to manage anemia and other toxicities. Would love to see analyses and measures focused on the impact of anemia/cytopenias beyond the FACT-P, and also transfusions, workup and health care utilization due to these AE’s #ASCOGU23

Great point! Agreed that anemia and its impact on health care utilization and QOL needs to be studied much more carefully

Successful 💪🏽session with all-star ⭐️line up of speakers!! Rare tumors (penile and seminoma) but lots of great data presented showing that we are indeed moving the needle forward! ASCO #GU23 Alexandros Papachristofilou +Dr Alice Yu + Dr Ben Ayres

“Patients see home not as a place but as a state of health they were previously in.” Thank you Daniel Lage, MD, MBA for your valuable insights and work! HMS Palliative Care MGH Palliative Care & Geriatric Medicine #hapc

So glad you’re keeping the tradition alive! Visit dinners are the best, so important to connect on a human/social level after spending so much time caring for complex/sick patients. Mass General Cancer Center Rick Lee 이재방

Interesting work. We effectively tell patients to figure it out on their own after hospital discharge. I wonder how that will go for seriously ill patients, those with poor health literacy, socioeconomic status, social supports, etc?? Thanks for sharing Ryan Nipp, MD, MPH

What’s the hardest part of being an oncologist? Giving difficult news to patients? Keeping up with rapid clinical and scientific advances? No, it’s “Having so many rules and regulations” buff.ly/3pnb2oO

Thoughtful discussion of the next frontier and challenges in value-based oncology: buff.ly/42X33ML I think the transition from FFS to capitated/global payments will be more challenging than most anticipate, but ultimately beneficial for patients & care deliver innovation

25% of days from diagnosis to death in metastatic GI cancer are spent in an inpt or outpt facility. Drives home the need for home-based oncology care delivery models as a win for patient experience and costs ascopubs.org/doi/full/10.12… JCO Oncology Practice Arjun Gupta Gabrielle Ryan Nipp, MD, MPH

Proud to highlight prostate cancer health disparities and the need for better screening and outreach alongside amazing colleagues Mass General Cancer Center Rick Lee 이재방 Brenda Lormil Beverly Moy #EdwinChoy Also, the Boston Rhythm Riders Line Dancers have some impressive moves, so fun!!

One more top 5 #bladdercancer -- which may be most anticipated GU track ESMO - Eur. Oncology #ESMO23 -- EV-302 looks to be game changer/paradigm shifting for our patients with metastatic #bladdercancer. Also double ADCs together and new data w/ FGFR inhibitors! OncoAlert Bladder Cancer Advocacy Network

APOS health equity scholar Angela Mendez sharing strategies to adapt supportive care interventions for minoritized men with prostate cancer on ADT. ⁦Daniel Lage, MD, MBA⁩ ⁦Mass General Cancer Center⁩ ⁦APOS⁩ #apos2024

Comparative effectiveness trial of early #palliative care delivered via telehealth versus in person among patients with advanced lung #cancer. meetings.asco.org/abstracts-pres… ASCO Mass General Cancer Center #ASCO24 Areej El-Jawahri Vicki Jackson #PalliativeCare

This is huge. Their NEJM 2010 pub set the standard, and now Temel & Greer have taken the next STEP to show us how palliative care can be scaled. This is the promise of routine PRO monitoring and intervening at the precise moment! now to implement.. #hapc #ASCO24

Insightful commentary by Daniel Lage, MD, MBA et al. Need to follow function when considering appropriateness for cancer Tx, as well as response to treatment once started. Regardless of cancer markers, if functional trajectory poor, then cancer Tx harms may > benefit. Cancer and Aging Research Group (CARG) #GeriOnc SIOG